The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $41.67 in the prior trading day, Protagonist Therapeutics Inc (NASDAQ: PTGX) closed at $42.57, up 2.16%. In other words, the price has increased by $2.16 from its previous closing price. On the day, 1.86 million shares were traded. PTGX stock price reached its highest trading level at $43.91 during the session, while it also had its lowest trading level at $39.6.
Ratios:
Our goal is to gain a better understanding of PTGX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.24 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.29. For the most recent quarter (mrq), Quick Ratio is recorded 12.48 and its Current Ratio is at 12.48. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 06, 2024, initiated with a Neutral rating and assigned the stock a target price of $47.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $62.
On November 05, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $58.Wedbush initiated its Outperform rating on November 05, 2024, with a $58 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 17 ’25 when Waddill William D. sold 4,000 shares for $54.25 per share. The transaction valued at 217,000 led to the insider holds 13,130 shares of the business.
WILLIAM D WADDILL bought 4,000 shares of PTGX for $219,120 on Mar 17 ’25. On Mar 13 ’25, another insider, MOLINA ARTURO MD, who serves as the Chief Medical Officer of the company, sold 30,514 shares for $55.74 each. As a result, the insider received 1,700,850 and left with 83,892 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 2613129728 and an Enterprise Value of 2319870720. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 10.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.02 while its Price-to-Book (P/B) ratio in mrq is 3.85. Its current Enterprise Value per Revenue stands at 5.34 whereas that against EBITDA is 9.145.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.53, which has changed by 0.5390456 over the last 52 weeks, in comparison to a change of 0.049593568 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $60.60, while it has fallen to a 52-week low of $24.22. The 50-Day Moving Average of the stock is -2.65%, while the 200-Day Moving Average is calculated to be 1.77%.
Shares Statistics:
The stock has traded on average 1.06M shares per day over the past 3-months and 1367420 shares per day over the last 10 days, according to various share statistics. A total of 61.04M shares are outstanding, with a floating share count of 57.88M. Insiders hold about 5.71% of the company’s shares, while institutions hold 100.05% stake in the company. Shares short for PTGX as of 1741910400 were 5129814 with a Short Ratio of 4.83, compared to 1739491200 on 4221220. Therefore, it implies a Short% of Shares Outstanding of 5129814 and a Short% of Float of 8.469999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Protagonist Therapeutics Inc (PTGX) is currently under the scrutiny of 8.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.05 and low estimates of -$0.75.
Analysts are recommending an EPS of between $0.16 and -$2.42 for the fiscal current year, implying an average EPS of -$1.23. EPS for the following year is -$1.07, with 8.0 analysts recommending between $2.95 and -$3.53.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for PTGX’s current fiscal year. The highest revenue estimate was $225M, while the lowest revenue estimate was $16M, resulting in an average revenue estimate of $98.78M. In the same quarter a year ago, actual revenue was $434.43M
